Mostrar el registro sencillo del ítem
dc.contributor.author | Palanca-Ballester, Cora![]() |
es_ES |
dc.contributor.author | Rodriguez-Casanova, Aitor![]() |
es_ES |
dc.contributor.author | Torres, Susana![]() |
es_ES |
dc.contributor.author | Calabuig-Fariñas, Silvia![]() |
es_ES |
dc.contributor.author | Exposito, Francisco![]() |
es_ES |
dc.contributor.author | Serrano, Diego![]() |
es_ES |
dc.contributor.author | Redin, Esther![]() |
es_ES |
dc.contributor.author | Valencia, Karmele![]() |
es_ES |
dc.contributor.author | Jantus-Lewintre, Eloisa![]() |
es_ES |
dc.contributor.author | Diaz-Lagares, Angel![]() |
es_ES |
dc.contributor.author | Montuenga, Luis![]() |
es_ES |
dc.contributor.author | Sandoval, Juan![]() |
es_ES |
dc.contributor.author | Calvo, Alfonso![]() |
es_ES |
dc.date.accessioned | 2024-04-29T18:08:28Z | |
dc.date.available | 2024-04-29T18:08:28Z | |
dc.date.issued | 2021-06 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/203845 | |
dc.description.abstract | [EN] Early alterations in cancer include the deregulation of epigenetic events such as changes in DNA methylation and abnormal levels of non-coding (nc)RNAs. Although these changes can be identified in tumors, alternative sources of samples may offer advantages over tissue biopsies. Because tumors shed DNA, RNA, and proteins, biological fluids containing these molecules can accurately reflect alterations found in cancer cells, not only coming from the primary tumor, but also from metastasis and from the tumor microenvironment (TME). Depending on the type of cancer, biological fluids encompass blood, urine, cerebrospinal fluid, and saliva, among others. Such samples are named with the general term "liquid biopsy" (LB). With the advent of ultrasensitive technologies during the last decade, the identification of actionable genetic alterations (i.e., mutations) in LB is a common practice to decide whether or not targeted therapy should be applied. Likewise, the analysis of global or specific epigenetic alterations may also be important as biomarkers for diagnosis, prognosis, and even for cancer drug response. Several commercial kits that assess the DNA promoter methylation of single genes or gene sets are available, with some of them being tested as biomarkers for diagnosis in clinical trials. From the tumors with highest incidence, we can stress the relevance of DNA methylation changes in the following genes found in LB: SHOX2 (for lung cancer); RASSF1A, RARB2, and GSTP1 (for lung, breast, genitourinary and colon cancers); and SEPT9 (for colon cancer). Moreover, multi-cancer high-throughput methylation-based tests are now commercially available. Increased levels of the microRNA miR21 and several miRNA- and long ncRNA-signatures can also be indicative biomarkers in LB. Therefore, epigenetic biomarkers are attractive and may have a clinical value in cancer. Nonetheless, validation, standardization, and demonstration of an added value over the common clinical practice are issues needed to be addressed in the transfer of this knowledge from "bench to bedside". | es_ES |
dc.description.sponsorship | A.C. and L.M. were funded by FIMA (Foundation for Applied Medical Research), ISCIIIFondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional Una manera de hacer Europa (PI19/00230, to AC; PI19/00098 to LMM), CIBERONC CB16/12/00443, AECC, and Ramón Areces Foundations (all to L.M.). J.S. was funded by FIS grant (PI19/00572) from the FEDER, FSE, Carlos III Health Institute (ISCIII) and INNVA1/2020/71 de la Línea 1 de Valorización y Transferencia a las empresas, de la Agencia Valenciana de la Innovación. E.J-L. was supported by the Spanish Health Institute Carlos III (ISCII, Fondo de Investigación Sanitaria: CB16/12/00350 and PI18/00266). S.T. was supported by the Generalitat Valenciana and Fondo Social Europeo, fellowship ACIF/2018/275. A.D-L. was funded by a contract Juan Rodés from Spanish Health Institute Carlos III (ISCIII) (JR17/00016) and by a research grant (PI18/00307) co-funded by ISCIII and the European Regional Development Fund (FEDER). A.R-C. was supported by the Roche-CHUS Joint Unit (IN853B2018/03) funded by GAIN, Consellería de Economía, Emprego e Industria . Fellowship support: E.R. FPU, Spanish Ministry of Education ; D.S., Juan de la Cierva-Incorporacion, Spanish Ministry of Science and Innovation . | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | MDPI AG | es_ES |
dc.relation.ispartof | Cancers | es_ES |
dc.rights | Reconocimiento (by) | es_ES |
dc.subject | Epigenetic biomarkers | es_ES |
dc.subject | Cancer | es_ES |
dc.subject | DNA methylation | es_ES |
dc.subject | Micro-RNAs | es_ES |
dc.subject.classification | BIOLOGIA CELULAR | es_ES |
dc.title | Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.3390/cancers13123016 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F00266/ES/INMUNOGRAMA NO INVASIVO. APROXIMACION MULTIDIMENSIONAL PARA CARACTERIZAR Y MONITORIZAR EL ESTATUS INMUNE EN CANCER DE PULMON./ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F00307/ES/DESARROLLO DE UNA FIRMA EPIGENETICA EN BIOPSIA LIQUIDA PARA PREDECIR LA RESPUESTA TERAPEUTICA EN CANCER COLORRECTAL METASTASICO./ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00098/ES/DESARROLLO DE NUEVAS HERRAMIENTAS MOLECULARES PARA EL MANEJO PERSONALIZADO DEL PACIENTE DE CANCER DE PULMON EN ESTADIO PRECOZ./ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00230/ES/EVALUACION DE YES1 COMO NUEVA DIANA TERAPEUTICA Y BIOMARCADOR DE RESPUESTA A DASATINIB EN CANCER DE PULMON/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00572/ES/FIRMA EPIGENETICA PARA DETECCION PRECOZ EN CANCER DE PULMON (CP): INVESTIGACION CLINICA CON DISPOSITIVO MEDICO Y GRHL2: GEN CLAVE EN LA TEM Y EN LA RESISTENCIA A INHIBIDORES DE TIROSIN KINASA DE EGFR EN CP/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00350/ES/CANCER/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00443/ES/CANCER/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/Xunta de Galicia//IN853B2018%2F03/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//ACIF%2F2018%2F275/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//JR17%2F00016/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AVI//INNVA1%2F2020%2F71/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials | es_ES |
dc.description.bibliographicCitation | Palanca-Ballester, C.; Rodriguez-Casanova, A.; Torres, S.; Calabuig-Fariñas, S.; Exposito, F.; Serrano, D.; Redin, E.... (2021). Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers. 13(12). https://doi.org/10.3390/cancers13123016 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/cancers13123016 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 13 | es_ES |
dc.description.issue | 12 | es_ES |
dc.identifier.eissn | 2072-6694 | es_ES |
dc.identifier.pmid | 34208598 | es_ES |
dc.identifier.pmcid | PMC8233712 | es_ES |
dc.relation.pasarela | S\461659 | es_ES |
dc.contributor.funder | Xunta de Galicia | es_ES |
dc.contributor.funder | Generalitat Valenciana | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Agència Valenciana de la Innovació | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad | es_ES |